| Product Unit Size | Cost | Quantity | Stock |
|---|
BGB-283 is a dual RAF/EGFR inhibitor. It inhibits BRAF(V600E)-activated ERK phosphorylation and cell proliferation in vitro. This activity slows cell proliferation and tumor growth in BRAF(V600E) colorectal cancer cell lines, something that BRAF inhibitors vemurafenib and dabrafenib have been unable to achieve.
| Cas No. | 1446090-79-4 |
|---|---|
| Purity | ≥98% |
| Formula | C25H17F3N4O3 |
| Formula Wt. | 478.43 |
| IUPAC Name | 5-({(1R,1aS,6bR)-1-[6-(Trifluoromethyl)-1H-benzimidazol-2-yl]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-5-yl}oxy)-3,4-dihydro-1,8-naphthyridin-2(1H)-one |
| Synonym | BGB 283, BGB283, Beigene-283, Lifirafenib |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Tang Z., Yuan X., et al. BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers. Mol Cancer Ther. 14(10):2187-97 (2015). PMID:26208524.